Efficacy and safety of acarbose in the treatment of Type 2 diabetes: Data from a 2-year surveillance study

Diabetes Research and Clinical Practice

Volumn 40, Issue 1, 1998, Pages 63-70

  Mertes, Gabriele ^a  

^a BAYER AG   (Germany)

Author keywords

Acarbose; Efficacy; Safety; Surveillance; Type 2 diabetes

Indexed keywords

ACARBOSE; BIGUANIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIVER ENZYME; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD GLUCOSE MONITORING; DIABETIC DIET; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ACARBOSE; AGED; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; POPULATION SURVEILLANCE; TRISACCHARIDES;

EID: 0031846458     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00045-X     Document Type: Article

References (19)

1. Truscheit E., Hillebrand I., Junge B., Mÿller L., Puls W., Schmidt D. Microbial alpha-glucosidase inhibitors: chemistry, biochemistry and therapeutic potential. Prog. Clin. Biochem. Med. 7:1988;17-99.
2. Hillebrand I., Boehme K., Frank G., Fink H., Berchthold P. The effects of the alpha-glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Res. Exp. Med. 175:1979;81-86.
3. W. Puls, H. Bischoff, H. Schutt, Pharmacology of amylase- and glucosidase-inhibitors, in: W. Creutzfeldt, U.R. Fslsch (Eds.), Delaying Absorption as a Therapeutic Principle in Metabolic Diseases, Thieme Verlag, Stuttgart, pp. 70-76.
4. Chiasson J.-L., Josse R.G., Leiter L.A.et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 19(11):1996;1190-1193.
5. Laubc H., Uhlmann M., Linn T.H.et al. Acarbose improves insulin sensitivity in obese patients with IGT. Diabetologia. 40(Suppl. 1):1997;321.
6. Qualmann C., Nauck M.A., Holst J.J.et al. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (Acarbose). Scand. J. Gastroenterol. 30:1995;892-896.
7. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Willms B., Creutzfeld W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
8. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care. 17:1994;561-566.
9. J. Larsen, P. Damsbo, GLP-1 Must be present continuously in order to obtain a good glycaemic control in NIDDM, Diabetes 46 (Suppl. 1) 186-187.
10. Braun D., Schsnherr U., Mitzkat H.J. Efficacy of acarbose monotherapy in patients with Type II diabetes: a double-blind study conducted in general practice. Endocrinol. Metab. 3:1996;275-280.
11. May C. Wirksamkeit und VertrSglichkeit von einschleichend dosierter Acarbose bei Patienten mit nichtinsulinpflichtigem Diabetes mellitus (Type-II-Diabetes) unter Sulfonylharnstofftherapie. Diabet. Stoffw. 4:1995;3-8.
12. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in NIDDM patients with dietary failure. Diabetologia. 39(Suppl. 1):1996;A230.
13. Lindstrsm J., Tuomilehto J., Spengler M. The effect of acarbose on dietary nutrient intake and metabolic control in NIDDM patients. Diabetologia. 39(Suppl. 1):1996;A195.
14. Wilson N.R., Chiasson J.-L., Hunt J.A.et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clin. Invest. Med. 4(18):1995;318-324.
15. J. Beyer, G. Schultz, H. Jaeger et al., Improvement of carbohydrate tolerance in insulin-dependent diabetics after administration of an alpha-glucosidase inhibitor demonstrated by the artificial pancreas, in: W. Creutzfeldt (Ed.), Proc. on First International Symposium on Acarbose. Excerpta Medica, Amsterdam, 1981, pp. 266-274.
16. Hanefeld M., Fischer S., Sehulsa J.et al. Therapeutic potentials of acarbose as firstline drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 14:1991;752-757.
17. Fslsch U.R., Spengler M., Boehme K., Sommerover B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated Type II diabetic subjects; two long-term comparative studies. Diabetes Nutr. Metab. 3:1990;63-68.
18. Spengler M., Cagatay M. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin. Invest. Med. 18:1995;325-331.
19. Ausschuß Pharmakotherapie des Diabetes mellitus der Deutschen Diabetes gesellschaft (Pharmacotherapy Board for Diabetes Mellitus of the German Diabetes Association), Zur klinischen Wirksamkeit und ZweckmSßigkeit von Acarbose und Metformin in der Therapie des Diabetes mellitus - Dokumentation und wissenschaftliche Stellungnahme, Diabet. Stoffw. 4 (1995) 407-421.